μ-Opioid receptor 6-transmembrane isoform: A potential therapeutic target for new effective opioids
نویسندگان
چکیده
منابع مشابه
μ-Opioid receptor 6-transmembrane isoform: A potential therapeutic target for new effective opioids.
The μ-opioid receptor (MOR) is the primary target for opioid analgesics. MOR induces analgesia through the inhibition of second messenger pathways and the modulation of ion channels activity. Nevertheless, cellular excitation has also been demonstrated, and proposed to mediate reduction of therapeutic efficacy and opioid-induced hyperalgesia upon prolonged exposure to opioids. In this mini-pers...
متن کاملcxcr4: a potential chemokine receptor for future regenerative therapeutic target
understanding the molecular mechanisms in regeneration could help the stem cell therapists to improve the clinical practices and could be considered a major milestone in the translation of stem cell research to clinics. chemokines have been described as one of the most significant singling networks in stem cells homing and regeneration of damaged organs. cxcr4/cxcl12 has been known as a key pla...
متن کاملA new splice of life for the μ-opioid receptor.
μ-Opioid agonists mediate their analgesic effect through GPCRs that are generated via alternate splicing of the Oprm1 transcript. While the majority of μ-opioids interact with receptors comprising the canonical 7 transmembrane (7TM) domain, a recently identified class of μ-opioids appears to require a 6TM domain variant. In this issue of the JCI, Lu and colleagues provide an in vivo proof-of-co...
متن کاملInterleukin-6: a new therapeutic target
The therapeutic success of biological agents, especially the tumour necrosis factor (TNF) inhibitors, has opened a new chapter in the book of therapies for rheumatoid arthritis. Nevertheless, more than 50% of patients may not respond by > 50% improvement. New compounds have recently entered the treatment arena. One of these is rituximab, which depletes B cells, and another, abatacept, interfere...
متن کاملCorrection: Interleukin-6: a new therapeutic target
JSS has received financial compensation from and served on advisory boards for Roche and is an investigator in clinical trials of tocilizumab. RNM has received consulting fees from Chugai; served on an ad hoc advisory board for Roche; and was responsible for the planning and preparation for publication of the Phase II European (CHARISMA) trial of tocilizumab with and without methotrexate. A pat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Progress in Neuro-Psychopharmacology and Biological Psychiatry
سال: 2015
ISSN: 0278-5846
DOI: 10.1016/j.pnpbp.2014.11.009